Prostate cancer affects millions of men in the United States, making early and accurate detection crucial for effective treatment. Advanced imaging technologies, like PSMA PET/CT scans, offer enhanced detection capabilities, enabling personalized treatment plans and improved patient outcomes. PSMA PET/CT scans with Illuccix are now recommended in clinical practice guidelines as the preferred alternative to conventional imaging, such as MRI or bone scans.
According to the American Cancer Society, over 3.1 million men in the United States live with prostate cancer, the second deadliest cancer for men. Delayed and inadequate diagnosis may limit treatment options and increase mortality risk. Ongoing PSA screenings and access to advanced imaging, such as PSMA PET/CT scans, are crucial for early detection and accurate diagnosis.
PSMA, or prostate-specific membrane antigen, is a protein overexpressed by prostate cancer cells. During a PSMA PET/CT scan, a small amount of tracer material coupled with a PSMA-specific molecule attaches to this protein. This tracer is then detected with a PET/CT scanner to reveal the location of prostate cancer cells wherever they are in the body, including where they have spread.
Illuccix® (kit for the preparation of Ga 68 gozetotide injection) is an advanced PSMA PET/CT imaging tracer developed by Telix Pharmaceuticals. A PET scan with Illuccix may detect tumors more accurately than conventional imaging methods, such as MRI or bone scans, providing greater clarity on the extent of your prostate cancer. This may provide physicians with the information they need to determine a personalized, appropriate treatment plan.
If you are facing a recent prostate cancer diagnosis, you may want to discuss with your physician if a PSMA PET/CT scan is right for you.
Selected important safety information
•There is a risk PET scan images with Illuccix may be misinterpreted or may be affected by other factors.
•Illuccix involves exposure to small amounts of radioactivity; long-term cumulative radiation exposure is associated with increased cancer risk.
•The most commonly reported adverse reactions to Illuccix include fatigue, nausea, constipation, and vomiting. These adverse reactions each typically occurred in 1.2% of the patients in clinical trials.
This is not the full important safety information. Full safety information and approved uses are available atilluccix.com/#safety-information
Learn More about a PSMA PET/CT Scan with Illuccix
